{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:41:02Z","timestamp":1791358862669,"version":"4.3.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.lfs.2022.121277","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T01:57:45Z","timestamp":1670810265000},"page":"121277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Deleterious effects of cardiomyocyte-specific prostaglandin E2 EP3 receptor overexpression on cardiac function after myocardial infarction"],"prefix":"10.1016","volume":"313","author":[{"given":"DruAnne L.","family":"Maxwell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy D.","family":"Bryson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Taube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2022.121277_bb0005","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.bbalip.2014.07.008","article-title":"Prostaglandin E2-induced inflammation: relevance of prostaglandin E receptors","volume":"1851","author":"Kawahara","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.lfs.2022.121277_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114858","article-title":"Prostaglandin E2 EP receptors in cardiovascular disease: an update","volume":"195","author":"Bryson","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.lfs.2022.121277_bb0015","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003291","article-title":"Prostaglandin E2 reduces cardiac contractility via EP3 receptor","volume":"9","author":"Gu","year":"2016","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.lfs.2022.121277_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yjmcc.2018.03.005","article-title":"Overexpression of prostaglandin E2 EP4 receptor improves cardiac function after myocardial infarction","volume":"118","author":"Bryson","year":"2018","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.lfs.2022.121277_bb0025","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.104.508333","article-title":"Cardiospecific overexpression of the prostaglandin EP3 receptor attenuates ischemia-induced myocardial injury","volume":"112","author":"Martin","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.lfs.2022.121277_bb0030","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1093\/cvr\/cvn312","article-title":"Overexpression of prostaglandin EP3 receptors activates calcineurin and promotes hypertrophy in the murine heart","volume":"81","author":"Meyer-Kirchrath","year":"2009","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.lfs.2022.121277_bb0035","doi-asserted-by":"crossref","first-page":"H1416","DOI":"10.1152\/ajpheart.00136.2003","article-title":"Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse","volume":"286","author":"LaPointe","year":"2004","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.lfs.2022.121277_bb0040","first-page":"271","article-title":"Isolation and culture of adult mouse cardiac myocytes","volume":"357","author":"O'Connell","year":"2007","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.lfs.2022.121277_bb0045","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1113\/EP085104","article-title":"Fractalkine neutralization improves cardiac function after myocardial infarction","volume":"100","author":"Gu","year":"2015","journal-title":"Exp. Physiol."},{"key":"10.1016\/j.lfs.2022.121277_bb0050","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1172\/JCI119360","article-title":"Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors","volume":"99","author":"Liu","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.lfs.2022.121277_bb0055","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1161\/HYPERTENSIONAHA.107.102590","article-title":"Reduced cardiac remodeling and function in cardiac-specific EP4 receptor knockout mice with myocardial infarction","volume":"51","author":"Qian","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.lfs.2022.121277_bb0060","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.bcp.2011.07.094","article-title":"UTP reduces infarct size and improves mice heart function after myocardial infarct via P2Y2 receptor","volume":"82","author":"Cohen","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.lfs.2022.121277_bb0065","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1161\/CIRCRESAHA.116.309624","article-title":"Macrophages in the remodeling failing heart","volume":"119","author":"Chen","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.lfs.2022.121277_bb0070","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.15212","article-title":"Pharmacological modulation of prostaglandin E(2) (PGE(2)) EP receptors improves cardiomyocyte function under hyperglycemic conditions","volume":"10","author":"Bosma","year":"2022","journal-title":"Physiol. Rep."},{"key":"10.1016\/j.lfs.2022.121277_bb0075","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1161\/CIRCULATIONAHA.113.007101","article-title":"CD4+ T cells promote the transition from hypertrophy to heart failure during chronic pressure overload","volume":"129","author":"Laroumanie","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.lfs.2022.121277_bb0080","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1097\/HJH.0000000000002456","article-title":"Adaptive immune disorders in hypertension and heart failure: focusing on T-cell subset activation and clinical implications","volume":"38","author":"Rai","year":"2020","journal-title":"J. Hypertens."},{"key":"10.1016\/j.lfs.2022.121277_bb0085","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1006\/jmcc.2000.1261","article-title":"Cytotoxic T lymphocytes are activated following myocardial infarction and can recognize and kill healthy myocytes in vitro","volume":"32","author":"Varda-Bloom","year":"2000","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.lfs.2022.121277_bb0090","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1097\/ALN.0000000000001031","article-title":"Down-regulation of MicroRNA-31 in CD4+ T cells contributes to immunosuppression in human sepsis by promoting TH2 skewing","volume":"124","author":"van der Heide","year":"2016","journal-title":"Anesthesiology"},{"key":"10.1016\/j.lfs.2022.121277_bb0095","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jaut.2017.12.006","article-title":"Molecular mechanisms underpinning T helper 17 cell heterogeneity and functions in rheumatoid arthritis","volume":"87","author":"van Hamburg","year":"2018","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.lfs.2022.121277_bb0100","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1084\/jem.20171773","article-title":"The immunology of hypertension","volume":"215","author":"Norlander","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.lfs.2022.121277_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2019.108842","article-title":"Dipeptidyl peptidase-4 inhibition prevents vascular aging in mice under chronic stress: modulation of oxidative stress and inflammation","volume":"314","author":"Xin","year":"2019","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.lfs.2022.121277_bb0110","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2741\/s33","article-title":"Chemokines and cardiac fibrosis","volume":"1","author":"Dobaczewski","year":"2009","journal-title":"Front. Biosci. (Schol. Ed)."},{"key":"10.1016\/j.lfs.2022.121277_bb0115","doi-asserted-by":"crossref","first-page":"H867","DOI":"10.1152\/ajpheart.00538.2019","article-title":"The deleterious role of the prostaglandin E2 EP3 receptor in angiotensin II hypertension","volume":"318","author":"Bryson","year":"2020","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.lfs.2022.121277_bb0120","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.immuni.2018.10.011","article-title":"Mitochondrial membrane potential regulates nuclear gene expression in macrophages exposed to prostaglandin E2","volume":"49","author":"Sanin","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.lfs.2022.121277_bb0125","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1113\/expphysiol.2004.027276","article-title":"Critical appraisal of the mouse model of myocardial infarction","volume":"89","author":"Degabriele","year":"2004","journal-title":"Exp. Physiol."},{"key":"10.1016\/j.lfs.2022.121277_bb0130","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1067\/mje.2002.117560","article-title":"Echocardiographic evaluation of ventricular remodeling in a mouse model of myocardial infarction","volume":"15","author":"Kanno","year":"2002","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"10.1016\/j.lfs.2022.121277_bb0135","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/00019501-200502000-00008","article-title":"Distinct mouse coronary anatomy and myocardial infarction consequent to ligation","volume":"16","author":"Kumar","year":"2005","journal-title":"Coron. Artery Dis."},{"key":"10.1016\/j.lfs.2022.121277_bb0140","first-page":"H1812","article-title":"Ventricular remodeling in a mouse model of myocardial infarction","volume":"274","author":"Patten","year":"1998","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.lfs.2022.121277_bb0145","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1054-8807(03)00129-7","article-title":"Myocardial infarction in the C57BL\/6J mouse: a quantifiable and highly reproducible experimental model","volume":"13","author":"Salto-Tellez","year":"2004","journal-title":"Cardiovasc. Pathol."},{"key":"10.1016\/j.lfs.2022.121277_bb0150","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1161\/hy02t2.102796","article-title":"Effect of ACE inhibitors and angiotensin II type 1 receptor antagonists on endothelial NO synthase knockout mice with heart failure","volume":"39","author":"Liu","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.lfs.2022.121277_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190300","article-title":"Ac-SDKP decreases mortality and cardiac rupture after acute myocardial infarction","volume":"13","author":"Nakagawa","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2022.121277_bb0160","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0895-7061(98)00235-0","article-title":"Reduction of myocardial infarct size by inhibition of inducible nitric oxide synthase","volume":"12","author":"Wang","year":"1999","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.lfs.2022.121277_bb0165","doi-asserted-by":"crossref","first-page":"H1900","DOI":"10.1152\/ajpheart.00379.2007","article-title":"Role of cardiac overexpression of ANG II in the regulation of cardiac function and remodeling postmyocardial infarction","volume":"293","author":"Xu","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.lfs.2022.121277_bb0170","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1161\/01.HYP.0000029095.23198.AD","article-title":"Role of AT2 receptors in the cardioprotective effect of AT1 antagonists in mice","volume":"40","author":"Xu","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.lfs.2022.121277_bb0175","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1113\/eph8702385","article-title":"Myocardial infarction and cardiac remodelling in mice","volume":"87","author":"Yang","year":"2002","journal-title":"Exp. Physiol."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320522009778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320522009778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T21:05:37Z","timestamp":1758402337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320522009778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":35,"alternative-id":["S0024320522009778"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2022.121277","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deleterious effects of cardiomyocyte-specific prostaglandin E2 EP3 receptor overexpression on cardiac function after myocardial infarction","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2022.121277","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"121277"}}